Patients with psoriasis and their compliance with medication
- PMID: 10495380
Patients with psoriasis and their compliance with medication
Abstract
Background: Poor compliance with treatment advice in chronic conditions, such as psoriasis, represents a major challenge to health care professionals. Previous research suggests that the rate of noncompliance in chronic conditions may be as high as 40%.
Objective: This study was designed to examine self-reported compliance in patients with psoriasis.
Methods: We undertook an anonymous postal survey sent to consecutive patients with psoriasis attending a tertiary psoriasis specialty clinic.
Results: Thirty-nine percent of participants reported that they did not comply with the treatment regimen recommended. The noncompliant group had a higher self-rated severity of psoriasis (t = -2.16, P =. 03), were younger (t = 3.28, P =.001), and had a younger age at onset (t = 2.35, P =.02) than those who were compliant. The noncompliant group reported that psoriasis had a greater impact on daily life (t = -2.23, P =.028), but general well-being was not significantly different from those who complied (t =.47, P = not significant).
Conclusion: Patients who reported intentional noncompliance with treatment advice were more likely to believe that both psoriasis and its treatment interfered with their quality of life but not overall well-being. The impact of treatment on daily life highlights the importance of joint decision making in planning treatment.
Similar articles
-
Objective assessment of compliance with psoriasis treatment.Arch Dermatol. 2004 Apr;140(4):408-14. doi: 10.1001/archderm.140.4.408. Arch Dermatol. 2004. PMID: 15096368
-
Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life.Br J Dermatol. 2005 Jun;152(6):1256-62. doi: 10.1111/j.1365-2133.2005.06576.x. Br J Dermatol. 2005. PMID: 15948990
-
Psoriasis has a major secondary impact on the lives of family members and partners.Br J Dermatol. 2007 Jun;156(6):1245-50. doi: 10.1111/j.1365-2133.2007.07881.x. Epub 2007 Apr 25. Br J Dermatol. 2007. PMID: 17459044
-
Patient-reported outcomes in psoriasis research and practice.Br J Dermatol. 2011 Dec;165(6):1361-2. doi: 10.1111/j.1365-2133.2011.10469.x. Epub 2011 Sep 29. Br J Dermatol. 2011. PMID: 21692769 Review. No abstract available.
-
[Treatment of psoriasis].Cah Coll Med Hop Paris. 1965 Dec 15;6(11):759-73. Cah Coll Med Hop Paris. 1965. PMID: 5323659 Review. French. No abstract available.
Cited by
-
Definition of treatment goals for moderate to severe psoriasis: a European consensus.Arch Dermatol Res. 2011 Jan;303(1):1-10. doi: 10.1007/s00403-010-1080-1. Epub 2010 Sep 21. Arch Dermatol Res. 2011. PMID: 20857129 Free PMC article.
-
Efalizumab in the treatment of psoriasis.Biologics. 2007 Sep;1(3):301-9. Biologics. 2007. PMID: 19707339 Free PMC article.
-
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).Arch Dermatol Res. 2007 Jun;299(3):111-38. doi: 10.1007/s00403-007-0744-y. Epub 2007 May 12. Arch Dermatol Res. 2007. PMID: 17497162 Free PMC article. Review.
-
Strategies to Optimize Adherence in Patients with Mycosis Fungoides.Cells. 2021 Dec 30;11(1):113. doi: 10.3390/cells11010113. Cells. 2021. PMID: 35011675 Free PMC article.
-
Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized.Dermatol Ther (Heidelb). 2015 Jun;5(2):91-105. doi: 10.1007/s13555-015-0075-4. Epub 2015 Apr 22. Dermatol Ther (Heidelb). 2015. PMID: 25899142 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
